PEP-Therapy

PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors

Cell penetrating peptide,protein-protein interaction,targeted therapies,oncology,clinical trial,and cancer

Pep-therapy operates in the Biotechnology research industry.

Pep-therapy's revenue is 1m - 10m

Pep-therapy has 11 - 50 employees.